Compare Quanta Services Inc (PWR) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quanta Services Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Quanta Services Inc trades at $652.65 (market cap $103.57B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Quanta Services Inc is far larger — about 13.8× Spyre Therapeutics Inc. Common Stock's market cap, and Quanta Services Inc pays a 0.06% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quanta Services Inc for 62 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PWR | SYRE | |
|---|---|---|
Market Cap | $103.57B | $7.52B |
Volume | 1,036,513 | 1,441,031 |
Sector | Industrials | Health |
52-Week High | $785.24 | $108.92 |
52-Week Low | $412.21 | $22.18 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $109.67B | $6.52B |
Dividend Yield | 0.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PWR trades at $660.53, down 4.93% for the day, but maintains strong analyst support with 27 buy ratings and a $802.08 consensus price target. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.24 surpassing expectations by 28%. Technical indicators show a bullish trend with support at $682 and resistance at $706. Revenue growth remains robust, climbing from $17.1B in 2022 to $28.5B in 2025.
PWR presents a compelling growth story with strong earnings momentum and a record $53B backlog supporting future revenue. However, elevated valuation ratios (P/E 78.82, EV/EBITDA 35.6) and negative cash flow trends pose risks. The stock offers 21% upside to consensus targets, but investors should weigh premium valuation against execution risks in large infrastructure projects.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
